Rentschler Biopharma SE, a global contract development as well as manufacturing organization (CDMO) for biopharmaceuticals, expanded its services in Japan and South Korea.
Japan and South Korea have well-developed and growing biopharma industries, making them important markets for biologics development. Rentschler Biopharma has been operating in the region for many years, working with a wide range of clients and relying on its local partner, Summit Pharmaceuticals International (SPI), to provide regional expertise and smooth collaboration.
To better serve Japanese clients, Rentschler Biopharma is working closely with its established partner SPI. This helps ensure smooth communication, local regulatory understanding, and project management that respects Japanese cultural practices.
The company focuses on flexibility and optimization for a wide range of biologics, from upstream/downstream development to GMP manufacturing, analytical testing, product characterization, and regulatory affairs. By leveraging its global sites in Germany and the U.S., Rentschler aims to shorten time-to-clinic and market while maintaining high quality and compliance for Japan and South Korea clients.
Executive Statement
According to Benedikt von Braunmühl, CEO at Rentschler Biopharma, they at Rentschler Biopharma are deeply grateful for the trust placed in us by their client partners in Japan and South Korea, and they look forward to deepening these relationships as well as building new strategic partnerships through continued collaboration.
